Posted: June 2017 By John K. Field, PhD, FRCPath and James L. Mulshine, MD, PhD There is now robust and consistent evidence for the cost-effectiveness of lung cancer computed tomography […] Read more

Posted: April 2017 By James L. Mulshine, MD, PhD and John K. Field, PhD, FRCPath Administration (VHA) clinicians reported their experience in implementing lowdose computed tomography (CT) lung cancer screening […] Read more

Posted: February 2017 By John K. Field, PhD, FRCPath, and James L. Mulshine, MD, PhD The Fourth IASLC Screening Strategy Advice Committee (SSAC) computed tomography (CT) screening workshop was held […] Read more

By Denise R. Aberle, MD The seminal National Lung Screening Trial (NLST) showed that lung cancer screening using low dose computed tomography (LDCT) resulted in a 20% decrease in lung […] Read more

By Gerard A. Silvestri, MD, MS, FCCP A recent population-based study suggested the incidence of pulmonary nodules detected by CT is around 1.5 million per year. This finding is no […] Read more

By James L. Mulshine, MD, PhD, Fred Hirsch, MD, PhD, and John K. Field, PhD, FRCPath Over the last fifteen years, the use of lowdose computed tomography (LDCT) for early […] Read more

By Prof. Fabien Calvo, MD, PhD Today, cancer research is facing several challenges. The genomics era has ushered in a host of new molecular therapies; however, most of these targeted […] Read more

By Professor John K. Field MA, PhD, BDS, FRCPath The advent of lung cancer computed tomography (CT) screening was initiated by the Early Lung Cancer Action Project (ELCAP) group in […] Read more